welcome, well
WP matters because it’s the end-game: without a commercial partner with infrastructure (Merck or otherwise), DCVax doesn’t scale. Advent was a governance/financial drag that had to be cleaned up before any serious partner could come in. You don’t sell a product like this globally while explaining away a CEO-controlled side business.
So no, the Advent deal doesn’t “soften” the importance of WP/Merck — it actually sharpens it. Advent cleanup just removes one red flag. What remains is the brutal reality that NWBO still doesn’t have the commercial engine for sales, reimbursement, distribution, or medical liaison. That only comes with a true pharma partner.
And let’s not forget the financial side: just read the 10-Qs. Management has been dangling multiple new trials, but everyone knows they don’t have the cash to fund them as an independent. Add to that the burden of ~90 Advent staff who now sit on NWBO’s books — that’s 10's of millions per year in fixed costs with zero sales revenue without sales team/support. If anything, the Advent acquisition makes it even more obvious: NWBO cannot carry this forward alone.
This is why WP matters more than ever. Without a major partner stepping in to absorb the trial commitments, the commercialization effort, and the headcount, NWBO is financially stranded. Advent cleanup was necessary, but it’s only one piece of the puzzle. The real make-or-break remains: who’s going to bankroll and execute the rollout?
all IMO
AI
Market Data 
Markets 
